p63 Antikörper

Produktnummer ABIN4949376

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch p63 in IF, IHC (p) und FACS. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für p63 Antikörper (ABIN4949376)

Target: p63 (TP63) (Tumor Protein P63 (TP63))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser p63 Antikörper ist unkonjugiert

Applikation: Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS)

Produktdetails anti-p63 Antikörper

Aufreinigung: Protein A affinity chromatography

Immunogen: Recombinant partial human p53 protein was used as the immunogen for this p63 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: The optimal dilution of the p63 antibody for each application should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the p63 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu p63

Target: p63 (TP63) (Tumor Protein P63 (TP63))

Andere Bezeichnung: p63 / Tumor protein 63

Hintergrund: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.